Coronary Artery Disease in Women: The Full Spectrum From MINOCA to Obstructive

Women’s coronary artery disease spans a spectrum invisible to standard testing. While men typically present with focal blockages visible on angiography, women develop disease across multiple vascular compartments simultaneously. Microvascular dysfunction affects the smallest vessels. Vasospasm strikes arteries that appear normal at rest. Plaque erosion causes heart attacks without the classic rupture. This broader spectrum explains why 50% of women with ischemia have non-obstructive coronary arteries, and why the same women face cardiovascular death rates equal to or exceeding those of men with visible blockages. Understanding this full spectrum changes diagnosis, treatment, and survival.

Women’s coronary artery disease is not less than men’s. It is different from men’s. The spectrum is wider. The presentation is subtler. The consequences are the same, or worse.

I remember the 54-year-old woman who arrived in my clinic with a stack of papers. Three emergency room visits for chest pain. Two normal angiograms. One cardiologist’s note reading “non-cardiac chest pain, consider anxiety.” She had classic angina: substernal pressure with exertion, relief with rest, reproducible pattern for eighteen months. Her coronary arteries were wide open on imaging. Her heart was dying anyway.

This is the clinical reality that standard cardiology training fails to address. The textbooks describe coronary artery disease as a problem of focal stenosis. A plaque builds. The lumen narrows. Blood flow drops. Ischemia develops. This model fits most men. It misses most women.

The Spectrum You Were Never Taught

Coronary artery disease in women exists across five distinct pathophysiologic domains. Each requires different diagnostic approaches. Each demands different treatments. All produce the same endpoint: damaged heart muscle and shortened lives.

The first domain is obstructive epicardial disease. This is the classic model. Atherosclerotic plaque narrows a major coronary artery by 50% or more. Blood flow becomes supply-limited during exertion. This accounts for roughly half of coronary disease presentations in women over 65. Tamis-Holland et al. 2019. 5 / Solid .

The second domain is coronary microvascular dysfunction. The large arteries are open, but the small resistance vessels fail to dilate normally. Blood cannot reach the tissue despite patent conduits. The WISE study documented this pattern in 50% of women with angina and non-obstructive coronary arteries. Pepine et al. 2010. These women faced a 2.5-fold higher risk of major adverse cardiac events over five years. Their angiograms looked normal. Their hearts were starving.

The third domain is epicardial vasospasm. The coronary artery constricts abnormally in response to triggers, sometimes to the point of complete occlusion. Provocative testing with acetylcholine reveals this problem in 33% of women with angina and non-obstructive arteries. Ong et al. 2014. The spasm occurs and resolves before standard angiography captures it.

The fourth domain is microvascular spasm. The small vessels constrict rather than the large ones. Same mechanism, different location, often harder to treat. Acetylcholine provocation identifies this pattern in 24% of ANOCA patients.

The fifth domain is plaque erosion. The plaque surface disrupts without the fibrous cap rupture seen in men. Thrombus forms on an intact plaque. Optical coherence tomography studies show plaque erosion as the culprit in 31% of MINOCA cases. Women constitute 75% of erosion cases. Jia et al. 2013. 4 / Promising .

These domains overlap. A woman can have mild obstructive disease plus microvascular dysfunction plus vasospasm. Each component contributes to her symptoms. Standard cardiology evaluates only one.

MINOCA: The Heart Attack That Doesn’t Look Like One

MINOCA stands for Myocardial Infarction with Non-Obstructive Coronary Arteries. The troponin rises. The EKG changes. The heart muscle dies. The angiogram shows open arteries.

This is not a rare phenomenon. MINOCA accounts for 6% of all myocardial infarctions. The meta-analysis by Pasupathy and colleagues established this prevalence across 28 studies and 176,502 patients. Pasupathy et al. 2015. 5 / Solid .

The sex distribution tells the story. Women represent 40% of MINOCA patients versus 24% of patients with MI and obstructive disease. The VIRGO study focused on young MI patients under 55 years. Among these young women, 11.1% had no obstructive coronary disease. Among young men, only 5.8% presented this way. Safdar et al. 2014.

The mechanisms behind MINOCA include plaque disruption without significant stenosis, coronary spasm, spontaneous coronary artery dissection, coronary embolism, and demand-supply mismatch. Each mechanism requires different treatment. A woman with vasospastic MINOCA needs calcium channel blockers. A woman with plaque erosion needs dual antiplatelet therapy. A woman with SCAD may need nothing beyond watchful waiting. Treating all MINOCA patients identically guarantees failure in most.

The prognosis of MINOCA is not benign. The 2019 AHA scientific statement documented mortality rates between 1% and 10% at one year depending on the underlying mechanism. Tamis-Holland et al. 2019. Women sent home with reassurance about their “clean arteries” face ongoing risk without appropriate secondary prevention.

ANOCA and INOCA: When Ischemia Hides

ANOCA is Angina with Non-Obstructive Coronary Arteries. INOCA is Ischemia with Non-Obstructive Coronary Arteries. Both describe the same clinical problem from different angles.

The prevalence is striking. Among patients undergoing coronary angiography for suspected ischemia, up to 50% of women have no obstructive stenosis. The EAPCI expert consensus documented this reality in 2020. Kunadian et al. 2020. These women are not imagining their symptoms. Their ischemia is real. The diagnostic test was wrong for the disease they have.

Women don’t die from what they have. Women die from what they hold.

They hold the memory of being dismissed. They hold the anxiety of symptoms that no test explains. They hold the doubt planted by physicians who interpret “normal angiogram” as “no disease.” They hold back from the emergency room the next time the chest pain returns. And sometimes they hold too long.

The CorMicA trial demonstrated what happens when physicians look for the full spectrum. Researchers randomized 151 patients with ANOCA to either standard care or thorough invasive coronary function testing with tailored therapy. The intervention group underwent acetylcholine provocation for spasm, adenosine testing for coronary flow reserve, and nitroglycerin assessment of epicardial function. Treatment was matched to the identified abnormality. Ford et al. 2018.

The results changed practice. Patients who received diagnosis-specific treatment had significantly better angina control at one year. Their quality of life improved. Their healthcare utilization decreased. Knowing the mechanism mattered.

The Microvascular Truth

Coronary microvascular dysfunction represents the clearest case of sex-specific cardiac pathology. The 2018 JACC State-of-the-Art Review by Taqueti and Di Carli laid out the science. Taqueti and Di Carli 2018. 5 / Solid .

The pathophysiology involves multiple mechanisms. Endothelial dysfunction impairs nitric oxide release. Smooth muscle dysfunction prevents normal vasodilation. Vascular remodeling reduces microvascular density. Inflammation drives all three processes. Estrogen withdrawal at menopause accelerates each mechanism.

The diagnostic threshold is specific. Coronary flow reserve below 2.0 indicates severe microvascular dysfunction. CFR between 2.0 and 2.5 is borderline abnormal. The 2020 ESC guidelines codified these cutoffs. Knuuti et al. 2020.

The prognostic implications are profound. The WISE study followed women with chest pain and non-obstructive coronaries for years. Those with CFR below 2.32 had 2.5 times the rate of major adverse cardiac events compared to women with normal flow reserve. Microvascular disease is not a benign condition. It is a risk equivalent.

Treatment targets the underlying mechanisms. ACE inhibitors improve endothelial function. Statins reduce vascular inflammation. Ranolazine modulates sodium channel function and improves myocardial oxygen efficiency. In clinical practice, ranolazine relieves symptoms in approximately 75% of women with microvascular angina who failed first-line therapy.

Why the Standard Workup Fails

Standard coronary angiography was designed to find focal obstructive lesions. The catheter injects dye. The fluoroscope captures shadows. Stenoses appear as narrowings in the contrast column. This technology revolutionized cardiology in the 1960s. It remains the reference standard.

The problem is what angiography cannot see.

Microvascular disease involves vessels too small for angiographic resolution. The arterioles and capillaries that constitute the resistance circulation are invisible to contrast imaging. A woman can have profound microvascular dysfunction with a completely normal angiogram.

Vasospasm occurs and resolves spontaneously. Unless the spasm happens during the angiogram, it will not be captured. Provocative testing with acetylcholine can induce spasm for diagnosis, but most labs do not perform this routinely.

Plaque erosion leaves the lumen intact. The disrupted endothelium and overlying thrombus occupy a fraction of the vessel wall. Optical coherence tomography or intravascular ultrasound can identify these lesions. Standard angiography shows a normal vessel.

Diffuse atherosclerosis affects the entire vessel gradually. There is no focal stenosis because the disease is everywhere. The vessel appears “normal” but is uniformly diseased. Fractional flow reserve and instantaneous wave-free ratio can unmask this pattern when visual assessment cannot.

The standard workup was built for one disease pattern. Women present with multiple patterns simultaneously. The mismatch explains the diagnostic failure rate.

The Clinical Framework: Mapping the Full Spectrum

I call this the Three Compartment Model of female coronary disease. Every woman with suspected ischemia should have each compartment evaluated before she is told her heart is fine.

Compartment one is the epicardial arteries. Standard angiography addresses this domain adequately for obstructive disease. For non-obstructive disease, add acetylcholine provocation testing to assess for vasospasm.

Compartment two is the microvasculature. Coronary flow reserve measurement quantifies this domain. Invasive CFR using a pressure wire with adenosine provides the gold standard. Non-invasive PET imaging offers an alternative when invasive testing is unavailable.

Compartment three is the myocardium itself. Cardiac MRI with stress perfusion imaging and late gadolinium enhancement assesses tissue-level disease. This modality detects previous infarction, ongoing ischemia, and alternative diagnoses like myocarditis or Takotsubo cardiomyopathy.

A complete evaluation interrogates all three compartments. An incomplete evaluation diagnoses nothing and treats nobody.

The 2019 ESC guidelines on chronic coronary syndromes incorporated this approach formally. The diagnostic algorithm for INOCA now includes coronary function testing as a Class IIA recommendation. Knuuti et al. 2020. The science supports thorough evaluation. The practice has been slow to follow.

Treatment Matched to Mechanism

Once the mechanism is identified, treatment becomes logical rather than empiric.

For obstructive epicardial disease, standard therapy applies. Aspirin, statin, beta-blocker, and revascularization when appropriate. Women benefit equally from these interventions when the disease pattern matches.

For coronary microvascular dysfunction, treatment targets endothelial health and metabolic efficiency. First-line agents include ACE inhibitors or ARBs for endothelial function, statins regardless of LDL level, and ranolazine for refractory symptoms. Beta-blockers help some patients but worsen symptoms in others by reducing heart rate without addressing the underlying vasodilatory defect.

For epicardial vasospasm, calcium channel blockers are first-line. Long-acting nitrates provide additional benefit. Beta-blockers are relatively contraindicated because they can worsen spasm through unopposed alpha-adrenergic vasoconstriction.

For microvascular spasm, calcium channel blockers again predominate. The response is less predictable than for epicardial spasm. Combination therapy with nitrates may be required.

For plaque erosion MINOCA, antiplatelet therapy is essential. Dual antiplatelet therapy for at least one year mirrors the approach to obstructive MI. Statins are mandatory for plaque stabilization. The absence of stenosis does not mean the absence of vulnerable plaque.

The therapeutic mistake is treating all women with suspected coronary disease identically. The physiologic mistake is assuming their disease is identical. Neither assumption holds.

What to Do at Your Next Appointment

Knowledge without action is useless. Here is what you can do with this information.

If you have chest pain, pressure, or unexplained dyspnea with exertion, do not accept “stress test normal” as a final answer. Standard exercise treadmill testing has a sensitivity of only 61% in women, versus 72% in men. A negative test does not exclude disease.

If you have had an angiogram showing non-obstructive coronary arteries but still have symptoms, request coronary function testing. Name the specific tests: acetylcholine provocation for spasm, coronary flow reserve with adenosine for microvascular function. Print this article and bring it to your cardiologist.

If you have been diagnosed with MINOCA, ask about cardiac MRI for mechanism identification. Ask about optical coherence tomography if MRI is non-diagnostic. Know that “clean arteries” does not mean “no disease.”

Request the following blood tests at your next visit: ApoB, Lp(a), fasting insulin, and high-sensitivity CRP. These markers capture risk that standard lipid panels miss. The ACC/AHA prevention guidelines support this expanded testing in intermediate-risk patients.

Ask your cardiologist whether your institution performs thorough coronary function testing. If not, ask for referral to a center that does. The WISE study was conducted at multiple academic centers. The CorMicA trial was performed in Glasgow. Expertise exists. Access is the barrier.

Frequently Asked Questions

Can I have a heart attack with clean coronary arteries?

Yes. MINOCA accounts for 6% of all myocardial infarctions, and women are disproportionately affected, representing 40% of cases. The coronary arteries appear open on standard angiography, but the heart attack is real. Plaque erosion, coronary spasm, or microvascular dysfunction caused the infarction through mechanisms invisible to standard imaging. These women need advanced testing including cardiac MRI, optical coherence tomography, and coronary function testing to identify the culprit mechanism and guide treatment. Without mechanism-specific therapy, recurrent events occur.

What tests should I request if I have chest pain but my angiogram was normal?

Request coronary reactivity testing with acetylcholine provocation to diagnose vasospasm. Request coronary flow reserve measurement with adenosine to assess microvascular function. Request cardiac MRI with stress perfusion and late gadolinium enhancement to evaluate the myocardium directly. The CorMicA protocol demonstrated that matching treatment to the diagnosed abnormality improves outcomes. Many labs do not perform these tests routinely. Ask specifically. If your institution lacks this capability, request referral to an academic center with a dedicated women’s heart program.

Why do women have different types of coronary artery disease than men?

Multiple factors converge. Estrogen withdrawal during perimenopause and menopause triggers endothelial dysfunction, reducing nitric oxide availability and impairing vasodilation. Women’s inflammatory profiles differ, with higher baseline CRP and different cytokine responses to vascular injury. Women’s plaques tend to erode rather than rupture, a pattern linked to superficial proteoglycan accumulation rather than deep lipid core instability. Women’s coronary arteries are smaller on average, making microvascular dysfunction more clinically apparent. These biological differences mean that diagnostic criteria derived from male populations miss female disease patterns systematically.

What medications work for microvascular angina?

Ranolazine improves symptoms in approximately 75% of women with microvascular angina who have failed conventional therapy. The medication reduces late sodium current in cardiac myocytes, improving diastolic function and oxygen efficiency without affecting heart rate or blood pressure. ACE inhibitors and ARBs improve endothelial function and should be prescribed regardless of blood pressure status. Statins reduce vascular inflammation and stabilize the microvasculature. Calcium channel blockers address any spastic component. Beta-blockers help some patients but worsen symptoms in others. Treatment requires trial and monitoring rather than rigid protocols.

Is microvascular disease as dangerous as blocked arteries?

Yes. The WISE study followed women with chest pain and non-obstructive coronary arteries for five years. Women with coronary flow reserve below 2.32 had a 2.5-fold higher rate of major adverse cardiac events including myocardial infarction, stroke, and cardiovascular death. This risk elevation matches or exceeds that seen in obstructive coronary disease. Microvascular dysfunction is not a benign finding. It is not “clean arteries.” It is diffuse vascular disease affecting the smallest vessels. These women require aggressive risk factor management including statin therapy, blood pressure optimization, and metabolic control.